As Biotechnology businesses, CRISPR Therapeutics AG (NASDAQ:CRSP) and Tiziana Life Sciences PLC (NASDAQ:TLSA), are affected by contrast. This especially applies to their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics AG 60 0.00 34.37M -0.46 0.00
Tiziana Life Sciences PLC 3 0.00 11.30M -0.07 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for CRISPR Therapeutics AG and Tiziana Life Sciences PLC.

Profitability

Table 2 provides us CRISPR Therapeutics AG and Tiziana Life Sciences PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics AG 57,388,545.67% -2.6% -2%
Tiziana Life Sciences PLC 390,922,299.87% 0% 0%

Analyst Ratings

CRISPR Therapeutics AG and Tiziana Life Sciences PLC Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CRISPR Therapeutics AG 0 0 3 3.00
Tiziana Life Sciences PLC 0 0 0 0.00

CRISPR Therapeutics AG’s upside potential is 10.16% at a $72 consensus price target.

Institutional & Insider Ownership

The shares of both CRISPR Therapeutics AG and Tiziana Life Sciences PLC are owned by institutional investors at 46.8% and 2.82% respectively. About 0.4% of CRISPR Therapeutics AG’s share are held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CRISPR Therapeutics AG 1% 49.37% 59.3% 63.07% 101.48% 153.31%
Tiziana Life Sciences PLC 4.39% -19.89% -24.8% -21.12% 0% -24.3%

For the past year CRISPR Therapeutics AG had bullish trend while Tiziana Life Sciences PLC had bearish trend.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link